X0306 4 2022-01-11 0 0001868734 CinCor Pharma, Inc. CINC 0001680200 Sofinnova Venture Partners X, L.P. C/O SOFINNOVA INVESTMENTS, INC. 3000 SAND HILL ROAD, BLDG. 4, SUITE 250 MENLO PARK CA 94025 0 0 1 0 0001680194 Sofinnova Management X, L.L.C. C/O SOFINNOVA INVESTMENTS, INC. 3000 SAND HILL ROAD, BLDG. 4, SUITE 250 MENLO PARK CA 94025 0 0 1 0 0001720685 Katabi Maha C/O SOFINNOVA INVESTMENTS, INC. 3000 SAND HILL ROAD, BLDG. 4, SUITE 250 MENLO PARK CA 94025 0 0 1 0 Common Stock 2022-01-11 4 C 0 5248949 A 5248949 I By Sofinnova Venture Partners X, L.P. Common Stock 2022-01-11 4 P 0 325000 16.00 A 5573949 I By Sofinnova Venture Partners X, L.P. Series A Preferred Stock 2022-01-11 4 C 0 13571428 0.00 D Common Stock 3991596 0 I By Sofinnova Venture Partners X, L.P. Series B Preferred Stock 2022-01-11 4 C 0 4275000 0.00 D Common Stock 1257353 0 I By Sofinnova Venture Partners X, L.P. Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date. The shares are directly held by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X. Dr. James I. Healy and Dr. Maha Katabi are managing members of SM X and may be deemed to share voting and investment power over the shares held by SVP X. Each of SM X and Dr. Katabi disclaims beneficial ownership of these shares except to the extent of its or her respective pecuniary interest therein. Dr. Healy is a director of the Issuer and files separate Section 16 reports. Sofinnova Venture Partners X, L.P., By /s/ Nathalie Auber, Attorney-in-Fact 2022-01-13 Sofinnova Management X, L.L.C., By /s/ Nathalie Auber, Attorney-in-Fact 2022-01-13 Maha Katabi, By /s/ Nathalie Auber, Attorney-in-Fact 2022-01-13